SuperworthLiminatus Pharma LIMN
- Market cap
- $3.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Liminatus Pharma's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $1.6M | $714.1K | $357.1K | $0 | n/a | n/a | n/a | n/a | $400K | $600K |
| SG&A | $96.4K | $195.1K | $186.1K | $167.1K | $264.2K+174% | $1.1M+473% | $701.2K+277% | $884.2K+429% | $700.9K+165% | $778.9K−30% |
| −$247 | −$909.2K | −$543.1K | −$167.1K | −$264.2K+106872% | −$1.1M+23% | −$701.2K+29% | −$884.2K+429% | −$1.1M+317% | −$1.4M+23% | |
| Interest expense | $62.8K | $77.2K | $92.7K | $106.2K | $115.5K+84% | $62.3K−19% | $19.1K−79% | $19.1K−82% | $18.6K−84% | $18.8K−70% |
| Net income | −$247 | −$961.2K | −$601.4K | −$229.8K | −$327.5K+132502% | $113.3K | −$1.8M+203% | −$8.2M+3456% | −$1.1M+243% | −$1.4M |
| −$123.50 | −$2.50 | −$1.50 | −$0.50 | −$1.00−99% | $0.00 | −$3.50+133% | −$15.00+2900% | −$1.50+50% | −$1.50 | |
| 2 | 350K | 350K | 350K | 350K+17499900% | 466K+33% | 540.2K+54% | 541.3K+55% | 720K+106% | 968K+108% |
R&D: Q1 FY24: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Liminatus Pharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LIMNLiminatus Pharma | $3.9M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Liminatus Pharma
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .